Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Depex-P is a combination syrup formulated with chlorpheniramine maleate, dextromethorphan hydrobromide, and phenylephrine hydrochloride. It is developed by Alde Medi Impex and is marketed for the relief of symptoms associated with the common cold, allergies, and upper respiratory tract infections, such as dry cough, nasal congestion, runny nose, and sneezing. Chlorpheniramine maleate is a first-generation antihistamine that acts as a competitive antagonist of the histamine H1 receptor, reducing allergic symptoms. Dextromethorphan hydrobromide is an antitussive agent that acts as a sigma-1 receptor agonist and a non-competitive NMDA receptor antagonist, suppressing the cough reflex in the brain. Phenylephrine hydrochloride is a selective alpha-1 adrenergic receptor agonist that acts as a decongestant by causing vasoconstriction in the nasal passages, thereby reducing swelling and congestion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Depex-P.